Prescribed benzodiazepines and suicide risk: A review of the literature

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 19, Issue 2, 2017, Pages

  Dodds, Tyler J ^a  

^a AUSTEN RIGGS CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; BENZODIAZEPINE DERIVATIVE; DIAZEPAM;

ANXIETY; ASSESSMENT OF HUMANS; BUNNEY HAMBURG RATING SCALE; CONTROLLED CLINICAL TRIAL (TOPIC); DEPRESSION; HUMAN; INSOMNIA; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SCHIZOPHRENIA; SUICIDAL BEHAVIOR; SUICIDE ATTEMPT; RISK; STATISTICS AND NUMERICAL DATA; SUICIDE;

BENZODIAZEPINES; HUMANS; RISK; SUICIDE;

EID: 85015352067     PISSN: 15235998     EISSN: 1555211X     Source Type: Journal    
DOI: 10.4088/PCC.16r02037     Document Type: Review

References (51)

1. Poulter MO, Du L, Weaver IC, et al. GABAA receptor promoter hypermethylation in suicide brain: implications for the involvement of epigenetic processes. Biol Psychiatry. 2008;64(8):645-652. doi:10.1016/j.biopsych.2008.05.028
2. Klempan TA, Sequeira A, Canetti L, et al. Altered expression of genes involved in ATP biosynthesis and GABAergic neurotransmission in the ventral prefrontal cortex of suicides with and without major depression. Mol Psychiatry. 2009;14(2):175-189. doi:10.1038/sj.mp.4002110
3. Sequeira A, Mamdani F, Ernst C, et al. Global brain gene expression analysis links glutamatergic and GABAergic alterations to suicide and major depression. PLoS One. 2009;4(8):e6585. doi:10.1371/journal.pone.0006585
4. Choudary PV, Molnar M, Evans SJ, et al. Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proc Natl Acad Sci U S A. 2005;102(43):15653-15658. doi:10.1073/pnas.0507901102
5. Merali Z, Du L, Hrdina P, et al. Dysregulation in the suicide brain: mRNA expression of corticotropin-releasing hormone receptors and GABA(A) receptor subunits in frontal cortical brain region. J Neurosci. 2004;24(6):1478-1485. doi:10.1523/JNEUROSCI.4734-03.2004
6. Lee R, Petty F, Coccaro EF. Cerebrospinal fluid GABA concentration: relationship with impulsivity and history of suicidal behavior, but not aggression, in human subjects. J Psychiatr Res. 2009;43(4):353-359. doi:10.1016/j.jpsychires.2008.04.004
7. Schneider B. Substance use disorders and risk for completed suicide. Arch Suicide Res. 2009;13(4):303-316. doi:10.1080/13811110903263191
8. Brower KJ, McCammon RJ, Wojnar M, et al. Prescription sleeping pills, insomnia, and suicidality in the National Comorbidity Survey Replication. J Clin Psychiatry. 2011;72(4):515-521. doi:10.4088/JCP.09m05484gry
9. Bachhuber MA, Hennessy S, Cunningham CO, et al. Increasing benzodiazepine prescriptions and overdose mortality in the United States, 1996-2013. Am J Public Health. 2016;106(4):686-688. doi:10.2105/AJPH.2016.303061
10. Curtin S, Warner M, Hedegaard H. Increase in suicide in the United States, 1999-2014. National Center for Health Statistics Data Brief No 241. April 22, 2016. CDC website. http://www.cdc.gov/nchs/products/databriefs/db241.htm. Accessed August 12, 2016.
11. Malik S, Kanwar A, Sim LA, et al. The association between sleep disturbances and suicidal behaviors in patients with psychiatric diagnoses: a systematic review and meta-analysis. Syst Rev. 2014;3(1):18. doi:10.1186/2046-4053-3-18
12. Fawcett J. Treating impulsivity and anxiety in the suicidal patient. Ann N Y Acad Sci. 2001;932(1):94-102, discussion 102-105. doi:10.1111/j.1749-6632.2001.tb05800.x
13. Maltsberger JT. The descent into suicide. Int J Psychoanal. 2004;85(pt 3):653-667. doi:10.1516/3C96-URET-TLWX-6LWU
14. Xiang Y-T, Weng Y-Z, Leung C-M, et al. Socio-demographic and clinical correlates of lifetime suicide attempts and their impact on quality of life in Chinese schizophrenia patients. J Psychiatr Res. 2008;42(6):495-502. doi:10.1016/j.jpsychires.2007.06.001
15. Weinstock LM, Gaudiano BA, Epstein-Lubow G, et al. Medication burden in bipolar disorder: a chart review of patients at psychiatric hospital admission. Psychiatry Res. 2014;216(1):24-30. doi:10.1016/j.psychres.2014.01.038
16. Lekka NP, Paschalis C, Beratis S. Suicide attempts in high-dose benzodiazepine users. Compr Psychiatry. 2002;43(6):438-442. doi:10.1053/comp.2002.35912
17. Fleischhacker WW, Kane JM, Geier J, et al. Completed and attempted suicides among 18,154 subjects with schizophrenia included in a large simple trial. J Clin Psychiatry. 2014;75(3):e184-e190. doi:10.4088/JCP.13m08563
18. Berman ME, Jones GD, McCloskey MS. The effects of diazepam on human self-aggressive behavior. Psychopharmacology (Berl). 2005;178(1):100-106. doi:10.1007/s00213-004-1966-8
19. Cowdry RW, Gardner DL. Pharmacotherapy of borderline personality disorder: alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. Arch Gen Psychiatry. 1988;45(2):111-119. doi:10.1001/archpsyc.1988.01800260015002
20. Gardner DL, Cowdry RW. Alprazolam-induced dyscontrol in borderline personality disorder. Am J Psychiatry. 1985;142(1):98-100. doi:10.1176/ajp.142.1.98
21. Brent DA, Emslie GJ, Clarke GN, et al. Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study. Am J Psychiatry. 2009;166(4):418-426. doi:10.1176/appi.ajp.2008.08070976
22. Fontanella CA, Campo JV, Phillips GS, et al. Benzodiazepine use and risk of mortality among patients with schizophrenia: a retrospective longitudinal study. J Clin Psychiatry. 2016;77(5):661-667. doi:10.4088/JCP.15m10271
23. Neutel CI, Patten SB. Risk of suicide attempts after benzodiazepine and/or antidepressant use. Ann Epidemiol. 1997;7(8):568-574. doi:10.1016/S1047-2797(97)00126-9
24. Park TW, Saitz R, Ganoczy D, et al. Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: case-cohort study. BMJ. 2015;350:h2698. doi:10.1136/bmj.h2698
25. Shih H-I, Lin M-C, Lin C-C, et al. Benzodiazepine therapy in psychiatric outpatients is associated with deliberate self-poisoning events at emergency departments: a population-based nested case-control study. Psychopharmacology (Berl). 2013;229(4):665-671. doi:10.1007/s00213-013-3127-4
26. Tiihonen J, Suokas JT, Suvisaari JM, et al. Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia. Arch Gen Psychiatry. 2012;69(5):476-483. doi:10.1001/archgenpsychiatry.2011.1532
27. Tiihonen J, Mittendorfer-Rutz E, Torniainen M, et al. Mortality and cumulative exposure to antipsychotics, antidepressants, and benzodiazepines in patients with schizophrenia: an observational follow-up study. Am J Psychiatry. 2016;173(6):600-606. doi:10.1176/appi.ajp.2015.15050618
28. Voaklander DC, Rowe BH, Dryden DM, et al. Medical illness, medication use and suicide in seniors: a population-based case-control study. J Epidemiol Community Health. 2008;62(2):138-146. doi:10.1136/jech.2006.055533
29. Gaertner I, Gilot C, Heidrich P, et al. A case control study on psychopharmacotherapy before suicide committed by 61 psychiatric inpatients. Pharmacopsychiatry. 2002;35(2):37-43. doi:10.1055/s-2002-25027
30. Neuner T, Hübner-Liebermann B, Haen E, et al; AGATE. Completed suicides in 47 psychiatric hospitals in Germany—results from the AGATE-study. Pharmacopsychiatry. 2011;44(7):324-330. doi:10.1055/s-0031-1284428
31. Rothschild AJ, Shindul-Rothschild JA, Viguera A, et al. Comparison of the frequency of behavioral disinhibition on alprazolam, clonazepam, or no benzodiazepine in hospitalized psychiatric patients. J Clin Psychopharmacol. 2000;20(1):7-11. doi:10.1097/00004714-200002000-00003
32. Taiminen TJ. Effect of psychopharmacotherapy on suicide risk in psychiatric inpatients. Acta Psychiatr Scand. 1993;87(1):45-47. doi:10.1111/j.1600-0447.1993.tb03328.x
33. Taiminen TJ, Kujari H. Antipsychotic medication and suicide risk among schizophrenic and paranoid inpatients: a controlled retrospective study. Acta Psychiatr Scand. 1994;90(4):247-251. doi:10.1111/j.1600-0447.1994.tb01588.x
34. Barak Y, Olmer A, Aizenberg D. Antidepressants reduce the risk of suicide among elderly depressed patients. Neuropsychopharmacology. 2006;31(1):178-181.
35. Raja M, Azzoni A, Koukopoulos AE. Psychopharmacological treatment before suicide attempt among patients admitted to a psychiatric intensive care unit. J Affect Disord. 2009;113(1-2):37-44. doi:10.1016/j.jad.2008.04.024
36. Albrecht B, Staiger PK, Hall K, et al. Benzodiazepine use and aggressive behaviour: a systematic review. Aust N Z J Psychiatry. 2014;48(12):1096-1114. doi:10.1177/0004867414548902
37. Acheson A, Reynolds B, Richards JB, et al. Diazepam impairs behavioral inhibition but not delay discounting or risk taking in healthy adults. Exp Clin Psychopharmacol. 2006;14(2):190-198. doi:10.1037/1064-1297.14.2.190
38. Deakin JB, Aitken MR, Dowson JH, et al. Diazepam produces disinhibitory cognitive effects in male volunteers. Psychopharmacology (Berl). 2004;173(1-2):88-97. doi:10.1007/s00213-003-1695-4
39. Bond AJ, Curran HV, Bruce MS, et al. Behavioural aggression in panic disorder after 8 weeks’ treatment with alprazolam. J Affect Disord. 1995;35(3):117-123. doi:10.1016/0165-0327(95)00053-4
40. Heinz AJ, Beck A, Meyer-Lindenberg A, et al. Cognitive and neurobiological mechanisms of alcohol-related aggression. Nat Rev Neurosci. 2011;12(7):400-413. doi:10.1038/nrn3042
41. Weerts EM, Tornatzky W, Miczek KA. Prevention of the pro-aggressive effects of alcohol in rats and squirrel monkeys by benzodiazepine receptor antagonists. Psychopharmacology (Berl). 1993;111(2):144-152. doi:10.1007/BF02245516
42. Gvion Y, Apter A. Aggression, impulsivity, and suicide behavior: a review of the literature. Arch Suicide Res. 2011;15(2):93-112. doi:10.1080/13811118.2011.565265
43. Brent DA, Oquendo M, Birmaher B, et al. Familial pathways to early-onset suicide attempt: risk for suicidal behavior in offspring of mood-disordered suicide attempters. Arch Gen Psychiatry. 2002;59(9):801-807. doi:10.1001/archpsyc.59.9.801
44. Hill AB. The environment and disease: association or causation? Proc R Soc Med. 1965;58(5):295-300.
45. Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168(12):1266-1277. doi:10.1176/appi.ajp.2011.10111704
46. Charlson F, Degenhardt L, McLaren J, et al. A systematic review of research examining benzodiazepine-related mortality. Pharmacoepidemiol Drug Saf. 2009;18(2):93-103. doi:10.1002/pds.1694
47. FDA requires strong warnings for opioid analgesics, prescription opioid cough products, and benzodiazepine labeling related to serious risks and death from combined use. August 31, 2016. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm518697.htm. Accessed November 13, 2016.
48. Barbanoj MJ, Clos S, Romero S, et al. Sleep laboratory study on single and repeated dose effects of paroxetine, alprazolam and their combination in healthy young volunteers. Neuropsychobiology. 2005;51(3):134-147. doi:10.1159/000085206
49. Paton C. Benzodiazepines and disinhibition: a review. Psychiatrist. 2002;26(12):460-462.
50. McCall WV, Benca RM, Rosenquist PB, et al. Hypnotic medications and suicide: risk, mechanisms, mitigation, and the FDA. Am J Psychiatry. 2017;174(1):18-25. doi:10.1176/appi.ajp.2016.16030336
51. Stepanski EJ, Wyatt JK. Use of sleep hygiene in the treatment of insomnia. Sleep Med Rev. 2003;7(3):215-225. doi:10.1053/smrv.2001.0246